- Home
- VSTM
VSTM
Verastem Inc.
as 04-18-2025 1:45pm EST
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 313.1M | IPO Year: | 2012 |
| Target Price: | $13.13 | AVG Volume (30 days): | 902.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.10 - $13.52 | Next Earning Date: | 05-08-2025 |
| Revenue: | $10,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 7.68% | Revenue Growth (next year): | 605.06% |
Stock Insider Trading Activity of Verastem Inc. (VSTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Calkins Daniel | VSTM | Chief Financial Officer | Mar 20 '25 | Sell | $6.97 | 91 | $630.89 | 86,374 | |
| Gagnon Robert E. | VSTM | Director | Mar 17 '25 | Sell | $6.95 | 284 | $1,973.80 | 34,193 | |
| Stuglik Brian M | VSTM | Director | Mar 17 '25 | Sell | $6.95 | 593 | $4,121.35 | 94,587 | |
| Paterson Dan | VSTM | President and CEO | Mar 17 '25 | Sell | $6.95 | 244 | $1,695.80 | 346,479 | |
| Paterson Dan | VSTM | President and CEO | Feb 4 '25 | Sell | $5.70 | 858 | $4,890.60 | 346,479 |
Latest Verastem Inc. News
VSTM Breaking Stock News: Dive into VSTM Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
MT Newswires
9 days ago
Jefferies Initiates Verastem at Buy With $15 Price Target
MT Newswires
11 days ago
Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating
Business Wire
12 days ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
23 days ago
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
Business Wire
25 days ago
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
MT Newswires
a month ago
RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating
Associated Press Finance
a month ago
Verastem: Q4 Earnings Snapshot
Compare VSTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.